A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors Cancer
Interventions: DRUG: ABBV-176
Sponsor: AbbVie